Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2019-08-31
DOI
10.1080/17512433.2019.1661775
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Larotrectinib in adult patients with solid tumours: a multicentre, open-label, phase I dose-escalation study
- (2019) D S Hong et al. ANNALS OF ONCOLOGY
- Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib.
- (2019) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
- (2019) Giles W. Robinson et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.
- (2019) Alexander E. Drilon et al. JOURNAL OF CLINICAL ONCOLOGY
- Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.
- (2019) Cornelis Martinus van Tilburg et al. JOURNAL OF CLINICAL ONCOLOGY
- Larotrectinib efficacy and safety in adult TRK fusion cancer patients.
- (2019) David S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Testing algorithm for identification of patients with TRK fusion cancer
- (2019) Frédérique Penault-Llorca et al. JOURNAL OF CLINICAL PATHOLOGY
- ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
- (2019) C Marchiò et al. ANNALS OF ONCOLOGY
- Larotrectinib Is Highly Active in Patients With Advanced Recurrent TRK Fusion Thyroid (TC) and Salivary Gland Cancers (SGC)
- (2018) L. Wirth et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
- (2018) Theodore W Laetsch et al. LANCET ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Use of Neoadjuvant Larotrectinib in the Management of Children With Locally Advanced TRK Fusion Sarcomas
- (2018) Steven G. DuBois et al. CANCER
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
- (2018) Alexander Drilon et al. Cancer Discovery
- 409OLarotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
- (2018) U N Lassen et al. ANNALS OF ONCOLOGY
- TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening
- (2018) Catherine M. Albert et al. JOURNAL OF CLINICAL ONCOLOGY
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
- (2018) Shivaani Kummar et al. Targeted Oncology
- Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
- (2017) Alexander Drilon et al. Cancer Discovery
- Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing
- (2017) Danielle A. Murphy et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
- (2016) Maria Menichincheri et al. JOURNAL OF MEDICINAL CHEMISTRY
- Infantile Fibrosarcoma WithNTRK3-ETV6Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2016) Ramamoorthy Nagasubramanian et al. PEDIATRIC BLOOD & CANCER
- Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials
- (2015) David M. Hyman et al. DRUG DISCOVERY TODAY
- Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials
- (2015) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
- (2015) Anna F. Farago et al. Journal of Thoracic Oncology
- An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
- (2015) R. C. Doebele et al. Cancer Discovery
- Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin
- (2014) Katherine A. Hoadley et al. CELL
- The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
- (2014) Elena Ardini et al. Molecular Oncology
- Anchored multiplex PCR for targeted next-generation sequencing
- (2014) Zongli Zheng et al. NATURE MEDICINE
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- TRKing Down an Old Oncogene in a New Era of Targeted Therapy
- (2014) Aria Vaishnavi et al. Cancer Discovery
- Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
- (2009) Kim-Son H. Nguyen et al. Clinical Lung Cancer
- Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
- (2008) M. H. Tomasson et al. BLOOD
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started